IR News 2018

Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2018

New Drug Application Filed for defibrotide sodium

NS-065/NCNP-01 (Viltolarsen) of Nippon Shinyaku’ in-house product Presentation on results of Phase I/II study in Japan

NS-065/NCNP-01 (Viltolarsen) of Nippon Shinyaku’ in-house product Presentation on results of Phase II study in US/Canada

Orphan drug designation granted to NS-73

Launch of the Anti-Cancer Agent / a Humanized Anti-CD20 Monoclonal Antibody “GAZYVA®"

Presentations on NS-065/ NCNP-01 at the 23rd International Annual Congress of the World Muscle Society

Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2018

Humanized Anti-CD20 Monoclonal Antibody, “GAZYVA® Intravenous Infusion 1000 mg,” Approved for the Treatment of CD20-Positive Follicular Lymphoma

Presentation of top line results of Phase I/II study of NS-065/NCNP-01 in Japan, for Duchenne muscular dystrophy

Presentation of top line results of US/Canada Phase II study of NS-065/NCNP-01, for Duchenne muscular dystrophy

Presentations on NS-065/ NCNP-01 at 2018 New Directions in Biology and Disease of Skeletal Muscle Conference

Outline of Consolidated Financial Results for the Year Ended March 31, 2018

Results of Exploratory Investigator-Initiated Clinical Trial of NS-065/NCNP-01

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2017